$3.24
2.56% today
Nasdaq, Nov 06, 09:17 pm CET
ISIN
US77313F1066
Symbol
RCKT

Rocket Pharmaceuticals, Inc. Stock price

$3.32
+0.14 4.40% 1M
-4.53 57.71% 6M
-9.25 73.59% YTD
-13.87 80.69% 1Y
-12.92 79.56% 3Y
-27.62 89.27% 5Y
-42.08 92.69% 10Y
-20.68 86.17% 20Y
Nasdaq, Closing price Wed, Nov 05 2025
+0.03 0.91%
ISIN
US77313F1066
Symbol
RCKT
Industry

Key metrics

Basic
Market capitalization
$358.2m
Enterprise Value
$108.0m
Net debt
positive
Cash
$271.5m
Shares outstanding
107.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 702.4
EV/Sales
- | 211.8
EV/FCF
negative
P/B
1.0
Financial Health
Equity Ratio
87.8%
Return on Equity
-55.9%
ROCE
-69.9%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$0.0 | $510.0k
EBITDA
$-253.5m | $-220.1m
EBIT
$-263.8m | $-251.4m
Net Income
$-257.6m | $-233.3m
Free Cash Flow
$-205.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
3.2% | 16.6%
EBIT
2.3% | 8.0%
Net Income
-1.6% | 9.8%
Free Cash Flow
2.4%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -43,161.3%
EBIT
-
Net
- | -45,741.1%
Free Cash Flow
-
More
EPS
$-2.3
FCF per Share
$-1.9
Short interest
22.4%
Employees
299
Rev per Employee
$0.0
Show more

Is Rocket Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

Rocket Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

22 Analysts have issued a Rocket Pharmaceuticals, Inc. forecast:

13x Buy
59%
8x Hold
36%
1x Sell
5%

Analyst Opinions

22 Analysts have issued a Rocket Pharmaceuticals, Inc. forecast:

Buy
59%
Hold
36%
Sell
5%

Financial data from Rocket Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 106 106
21% 21%
-
- Research and Development Expense 158 158
12% 12%
-
-253 -253
3% 3%
-
- Depreciation and Amortization 10 10
24% 24%
-
EBIT (Operating Income) EBIT -264 -264
2% 2%
-
Net Profit -258 -258
2% 2%
-

In millions USD.

Don't miss a Thing! We will send you all news about Rocket Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rocket Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
14 days ago
Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Rocket (RCKT) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in  Rocket securities between February 27, 2025 to May 26, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at ...
Neutral
Business Wire
23 days ago
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of the Biologics License Application (BLA) for KRESLADI™ (marnetegragene aut...
Neutral
Business Wire
27 days ago
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that on October 6, 2025, the Compensation Committee of Rocket's Board of Directors approved the grant of inducement equity incentive awards to its newly-hi...
More Rocket Pharmaceuticals, Inc. News

Company Profile

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded in 1999 and is headquartered in New York, NY.

Head office United States
CEO Gaurav Shah
Employees 299
Founded 1999
Website www.rocketpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today